RIVFLOZA Drug Patent Profile
✉ Email this page to a colleague
When do Rivfloza patents expire, and when can generic versions of Rivfloza launch?
Rivfloza is a drug marketed by Novo and is included in one NDA. There are six patents protecting this drug.
This drug has thirty-seven patent family members in seventeen countries.
The generic ingredient in RIVFLOZA is nedosiran sodium. One supplier is listed for this compound. Additional details are available on the nedosiran sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Rivfloza
Rivfloza will be eligible for patent challenges on September 29, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be September 29, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for RIVFLOZA
International Patents: | 37 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
What excipients (inactive ingredients) are in RIVFLOZA? | RIVFLOZA excipients list |
DailyMed Link: | RIVFLOZA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RIVFLOZA
Generic Entry Date for RIVFLOZA*:
Constraining patent/regulatory exclusivity:
TO LOWER URINARY OXALATE LEVELS IN CHILDREN 9 YEARS OF AGE AND OLDER AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1) AND RELATIVELY PRESERVED KIDNEY FUNCTION, E.G., EGFR GREATER THAN OR EQUAL TO 30 ML/MIN/1.73 M^2 NDA:
Dosage:
SOLUTION;INJECTION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for RIVFLOZA
RIVFLOZA is protected by six US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RIVFLOZA is ⤷ Try a Trial.
This potential generic entry date is based on TO LOWER URINARY OXALATE LEVELS IN CHILDREN 9 YEARS OF AGE AND OLDER AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1) AND RELATIVELY PRESERVED KIDNEY FUNCTION, E.G., EGFR GREATER THAN OR EQUAL TO 30 ML/MIN/1.73 M^2.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting RIVFLOZA
Therapeutic inhibition of lactate dehydrogenase and agents therefor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Therapeutic inhibition of lactate dehydrogenase and agents therefor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Therapeutic inhibition of lactate dehydrogenase and agents therefor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods and compositions for inhibiting expression of LDHA
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Therapeutic inhibition of lactate dehydrogenase and agents therefor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1)
FDA Regulatory Exclusivity protecting RIVFLOZA
TO LOWER URINARY OXALATE LEVELS IN CHILDREN 9 YEARS OF AGE AND OLDER AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1) AND RELATIVELY PRESERVED KIDNEY FUNCTION, E.G., EGFR GREATER THAN OR EQUAL TO 30 ML/MIN/1.73 M^2
Exclusivity Expiration: ⤷ Try a Trial
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-001 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-003 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-003 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-001 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-001 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-002 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-003 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RIVFLOZA
See the table below for patents covering RIVFLOZA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20200078530 | LDHA의 발현을 억제하기 위한 방법 및 조성물 | ⤷ Try a Trial |
Poland | 3679141 | ⤷ Try a Trial | |
South Korea | 102609396 | ⤷ Try a Trial | |
European Patent Office | 3204497 | INHIBITION THÉRAPEUTIQUE DE LA LACTATE-DÉSHYDROGÉNASE ET AGENTS ASSOCIÉS (THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR) | ⤷ Try a Trial |
Israel | 251643 | מעכב טיפולי של לקטאט דיהידרוגנאז וגורמים שלהם (Therapeutic inhibition of lactate dehydrogenase and agents therefor) | ⤷ Try a Trial |
Japan | 7308213 | ⤷ Try a Trial | |
China | 107257858 | 乳酸脱氢酶的治疗性抑制及其试剂 (Therapeutic inhibition of lactate dehydrogenase and agents therefor) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |